まとめ
抗カルシウム剤であるヴェラパミルは,血圧と血管抵抗を低下させることで,冠動脈疾患 (CAD) の患者の心臓機能を改善します. 血管拡張効果は,潜在的ネガティブなイノトロプ効果を上回り,全体的に左心室のパフォーマンスを向上させます.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- ベラパミルは,カルシウムチャネルブロッカーであり,心律不整症の治療に広く使用されています.
- ヴェラパミルが心疾患患者の心筋機能を抑える可能性について懸念があります.
研究 の 目的:
- 冠動脈疾患 (CAD) の患者の心筋機能に対する静脈内ベラパミルの影響を調査する.
主な方法:
- 血液動力学と血管学の研究は,心不全のないCAD患者の20人に実施されました.
- 患者は静脈内ベラパミルボラス投与を受け,その後連続注入を受けた.
主要な成果:
- ベラパミルは,平均大動脈圧と全身血管抵抗を著しく低下させた.
- 心臓指数,円周線維の縮小速度,射出分数を含む左心室 (LV) の性能指数は,著しく改善した.
- 心拍数とLVアシンर्जीはほとんど変わらなかった.
結論:
- CAD患者では,ヴェラパミルの強力な血管拡張作用は,その内在的な負のイノトロプ効果を補償する.
- ヴェラパミルは,冠動脈疾患の患者の全般的な心臓機能を改善します.
関連する概念動画
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Myocarditis I: Introduction
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...


